The type III secretion system is an important Pseudomonas aeruginosa-virulence determinant in animal models of infection and in humans. Antibody-mediated inhibition of the PcrV protein, an essential component of this system, might abrogate the Pseudomonas aeruginosa ability to damage epithelial cells, neutrophils, and macrophages, thereby limiting its pathogenicity. The objective of the trial was to determine the safety, pharmacokinetics, and ability to prevent Pseudomonas aeruginosa ventilator-associated pneumonia of KB001, a recombinant, PEGylated, engineered, human Fab′ fragment that specifically binds to a Pseudomonas aeruginosa PcrV epitope and blocks its function.
D espite the availability of antibiotics to which the bacterium is susceptible, morbidity and mortality associated with Pseudomonas aeruginosa (Pa) ventilator-associated pneumonia (VAP) remain high, thereby justifying any effort to prevent its occurrence in patients receiving prolonged mechanical ventilation (MV) (1) (2) (3) (4) (5) . As for many other opportunistic Gram-negative bacilli, increasing antibiotic resistance has further hindered Pa-VAP therapeutic management (6) (7) (8) . Even resistance to carbapenems and the other drugs, including piperacillin-tazobactam and cefepime, most effective against Pseudomonas, has now been described (8) (9) (10) . Rather than focusing on therapeutics targeting in vitro pathogen viability (e.g., conventional antibiotics), an alternative strategy is to target infection-essential functions (e.g., virulence factors required to cause host damage and disease) (11, 12) . This approach has several potential advantages, including expanding the repertoire of bacterial targets, preserving the host's endogenous microbiome and exerting less selective pressure, which might engender decreased resistance.
The type III secretion system (TTSS) is a major Pa-virulence determinant in animal models of infection and is required for systemic Pa spread in a mouse pulmonary challenge model (13) (14) (15) (16) (17) . In human infections, functional TTSS expression corresponds to poor prognoses (18) (19) (20) (21) . TTSS consists of a complex secretion and translocation apparatus, whose needlelike structure is able to inject up to four different exotoxins (ExoS, ExoT, ExoU, and ExoY) directly into the eukaryocyte cytoplasm, with different Pa strains secreting different exotoxins (22) (23) (24) (25) (26) . Furthermore, in the absence of exotoxins, the TTSS can directly mediate macrophage and neutrophil cytotoxicity through a cell-death process called "oncosis"; macrophagereleased factors trigger bacterial swarming and lead to direct cell-membrane perforation (27, 28) . Pertinently, the needle-tip protein, PcrV, is an essential component of all these TTSS functions (29) .
KB001 is an investigational, PEGylated, engineered human Fab´ fragment that specifically binds to a Pa-PcrV epitope and inhibits its function. This antibody had potent TTSS neutralization activity and protected cultured cells against exotoxin-mediated cytotoxicity and exotoxin-independent TTSS-mediated macrophage oncosis (20, (30) (31) (32) (33) . KB001 was also active in vivo in an acute pulmonary infection model in mice, preventing death, recovering body temperature, and enhancing bacterial clearance from the lungs (33) (34) (35) . Therefore, KB001 binding to PcrV might prevent or treat serious infections in intensive care unit (ICU) patients with pulmonary Pa colonization and would not be expected to contribute to multidrug resistance. This phase-2a dose-finding study was conducted to determine the safety, pharmacokinetics (PK), and potential usefulness of KB001 to prevent Pa-VAP in ICU patients requiring prolonged MV, who were colonized, but not infected, with this bacterium.
MATERIALS AND METHODS
Study Design and Treatments. This prospective, multicenter, randomized, placebocontrolled, double-blind, parallel-group, phase-2a study was conducted at ten French centers from April 2008 to July 2009. A centralized randomization system assigned eligible patients 1:1:1 to receive 3-or 10-mg/kg KB001, or placebo. The randomization program was password protected and accessed by the principal investigators after the patient had met the selection criteria. The patient's initials were entered and then treatment allocation was assigned. Trial medication was administered intravenously as a single infusion within 72 hrs of qualifying pulmonary Pa-culture results. KB001 was diluted in preservative-free 0.9% saline. The Comité de Protection des Personnes de Paris Saint-Louis approved the protocol; all patients or their relatives/surrogates gave written informed consent.
Study centers followed institutional practices for VAP prevention in accordance with current recommendations, including hand hygiene with alcohol-based sanitizer; gloveand-gown use; sedation administration and weaning protocols; keeping patients in a semirecumbent (30°-45°) rather than supine position; monitoring to maintain endotracheal tube cuff pressure >20 cm H 2 O; and mouth decontamination with oral chlorhexidine or other antiseptics (36) (37) (38) , and were encouraged to avoid changing practices during the study.
Patient Selection. Adult (≥18 yrs old) patients on MV, who were expected to remain so for ≥3 days and receiving no antibiotics or having no antibiotic change within 3 days before randomization (day [D] 0) were included as soon as surveillance quantitative endotracheal aspirate (ETA) (≥10 3 colony forming unit [CFU]/ mL) and/or bronchoalveolar lavage (BAL) fluid (≥10 2 but <10 4 CFU/mL) cultures identified Pa colonization. Reasons for study exclusion included the following: known chronic Pa pulmonary infection (i.e., cystic fibrosis), known or suspected concomitant bacterial infection requiring additional systemic treatment, any new antibiotic with anti-Pa activity within the 72 hrs preceding cultures documenting pulmonary Pa colonization, patients expected not to survive ≥3 days or to be transferred to another institution during the study period, participation in another investigational study within 28 days, and/or pregnancy.
Measurements and Assessments. Demographic, physiologic, and radiographic features, coexisting conditions, medical history, and MV characteristics were recorded at study entry, as were Simplified Acute Physiology II, Sequential Organ Failure Assessment, and Clinical Pulmonary Infection scores (39) (40) (41) . ETA specimens were obtained for Gram staining and culture using a sputum suction trap (Vygon, Écouen, France), as previously described by Jourdain et al (42) . Fiberoptic bronchoscopy and BAL were done according to each ICU's protocol. However, in most ICUs, BAL was performed by instilling a total of six 20-mL aliquots of sterile, nonbacteriostatic saline, as described by Chastre et al (2, 43) and Meduri et al (44) . The liquid recovered after the first aliquot was discarded and the remaining lavage fluids were pooled. Daily study evaluations included clinical pulmonary infection score calculation, hematology and blood chemistries, urine output, ventilation parameters, chest X-ray, concomitant medications, and adverse events (AEs). Blood and ETA samples were collected for quantitative cultures and PK analyses on day (D) 0, D1, D2, D3, D7, D14, D28, and when pneumonia was diagnosed. The first ETA sample taken after a subject had been entered into the study was tested for Pa-TTSS genotype, using a commercially available polymerase chain reaction method, with a Pa-specific primer and proprietary TTSS-specific primers detecting PcrV, ExoS, and ExoU. Serum and ETA/BAL KB001 concentrations were measured for all patients with a validated enzyme-linked immunosorbent assay at a central laboratory (KaloBios Pharmaceuticals, Inc, South San Francisco, CA). Serum samples were tested for anti-KB001 antibodies on D0, D14, and D28 with a previously described bridging enzyme-linked immunosorbent assay (45) .
Extreme vigilance for pneumonia onset was maintained throughout the study to detect any possible pulmonary infection episode: distal pulmonary secretions were obtained with bronchoscopic or nonbronchoscopic techniques before any new antibiotics were started, as soon as a patient became febrile, had purulent tracheal secretions, and/or a new pulmonary infiltrate developed or an existing infiltrate progressed (46) . Distal pulmonary secretions were also collected, whenever possible, when unexplained hemodynamic instability required higher vasopressor doses or their introduction; blood-gas values deteriorated inexplicably; or an intercurrent event imposed an urgent antibiotic change for any reason. BAL and ETA samples obtained for cultures were also tested for presence of KB001, except when contaminated with blood. Other complicating infections (bloodstream, intraabdominal, postoperative wounds, tracheotomy stomal site requiring antibiotics, surgical débridement, and/or urinary tract infection) were also recorded. Any antibiotic use was noted daily until D28, as was the patient's status at discharge from the hospital and 28 days postrandomization.
Analysis Populations and Study End points. The safety population included all randomized patients who received a study drug dose (intention-to-treat population). All patients with serum KB001-level data with which PK parameters could be determined comprised the PK population. The efficacy population consisted of all treated patients satisfying the enrollment criteria for Pa-positive respiratory microbiology and considered not clinically infected with this bacterium at inclusion by the Adjudication Committee.
The primary end point was KB001 safety and tolerability, as assessed by the frequency and severity of treatment-related AEs. Study personnel recorded AEs during the infusion and the 2 hrs thereafter and at all protocol-required study visits. AEs were graded according to the Adult Toxicity Table, as adapted by the National Institute of Allergy and Infectious Diseases. As indicated above, human antibodies directed against the anti-PcrV Fab´ fragment were sought on D0, D14, and D28.
Prespecified secondary end points included serum and lung KB001 PK, and Pa-pneumonia rates observed within 28 days of study treatment infusion. At study completion, a blinded Adjudication Committee meeting was held wherein three reviewers (BF, JC, and an external expert Marc Bonten) independently assessed all pertinent data to determine whether or not Pa pneumonia had occurred in patients prerandomization and/or postrandomization. Pa pneumonia was diagnosed when: quantitative distal BAL-fluid and/or ETA cultures grew, respectively, ≥10 4 and ≥10 5 CFU/mL, in association with compatible clinical findings; blood and respiratory secretion cultures grew Pa; or the patient had received new antibiotics effective against Pa and the blinded Adjudication Committee considered the diagnosis highly probable, based on the review of all clinical and microbiologic data, including repeated clinical pulmonary infection scores determinations and the subsequent disease course. Disagreements among the three experts were resolved by consensus. Those decisions were used to determine the percentages of patients in each group who developed Pa pneumonia through D28 and Pa-infection-free survivors on D28, excluding uncomplicated urinary tract infections.
Statistical Analyses. Although the sample size was not formally calculated because of the exploratory nature of the trial, ≥12 patients assessable for safety and efficacy in each group were considered sufficient for this pilot phase-2a trial. All data are reported as median [ranges] unless otherwise specified. Overall comparisons at baseline among treatment arms used a Mann-Whitney U test or twosided Fisher's exact test, as appropriate, with significance set at p =.05. Means ± sd serum KB001-PK parameters and KB001 penetration into the airway fluid compartment, i.e., in ETA sample concentrations, for each treatment group and time were compared with noncompartmental methods. No imputation for missing data was performed. Two-sided 90% confidence intervals were calculated to determine percentage-point differences between Pa pneumonia and Pa-infection-free survival rates of KB001-treated patients (pooling both concentrations) or placebo. Analyses were conducted with SAS v9.0 software (SAS Institute, Cary, NC).
RESULTS

Study Populations and Patient Characteristics.
Among the 41 patients enrolled in the trial, randomization assigned 14 to receive the 3-mg/kg KB001 dose, 14 the 10-mg/kg KB001 dose, and 13 the placebo ( Fig. 1) . Two patients, one each in the 3-mg/kg KB001 or placebo group, were successfully weaned off MV before the assigned treatment could be administered and were excluded, leaving 39 intentionto-treat-population patients, respectively, 13 and 14 in the 3-and 10-mg/kg KB001 groups, and 12 in the placebo group. All 39 were also included in the PK analysis population. The blinded Adjudication Committee determined that two placebogroup patients, and one patient in each of the KB001-treated groups had ongoing Pa VAP on D0 and were thus excluded from the efficacy population ( Fig. 1) .
Baseline demographic parameters, disease severity, and indications for MV were similar for the three study groups ( Table 1) : >90% of patients in each group had received broad-spectrum antibiotics within the 14 days preceding enrollment and most had been ventilated for ≥7 days before Pa-colonization documentation. D0 ETA-Pa burden was high for all groups, with respective medians of 5.5, 3.9, and 5.0 log 10 CFU/mL in 3-or 10-mg/ kg KB001-treated patients and placebo recipients. Among 39 ETA samples tested with the Pa probe (each sample representing a different patient), only one sample was deemed negative, corresponding to a patient identified by culture as having a low Pa burden (<2.1 log 10 CFU/mL). All other patients were colonized with polymerase chain reactiondetectable Pa and carried a PcrV gene. Among the positive samples tested (each sample representing a different subject), 31 of 38 were PcrV + ExoS + ExoU -, 5 of 38 were PcrV + ExoS -ExoU + , and 2 of 38 were PcrV + ExoS + ExoU + .
Safety and Tolerability. No significant AE or severe AE differences were found among the three patient groups, with 100% of the 3-mg/kg and 78.6% of the 10-mg/kg KB001-treated groups, and 91.7% of the placebo recipients experiencing at least one AE ( Table 2 ). Most AEs were mild or moderate in severity. At least one severe AE was reported for 15 (55.5%) KB001-treated patients and seven (58.3%) placebo recipients (NS); all were expected for such seriously ill ICU patients. AEs considered possibly related to a study treatment (all mild) were experienced by one patient in each of the KB001-treated groups (transiently increased serum aminotransferase activity, diarrhea) and two placebo recipients (leukocytosis, cholestasis). No infusionassociated AEs occurred. Six patients died, one 3-mg/kg KB001-treated, two 10-mg/kg KB001-treated, and three placebo recipients: all were due to irreversible multiorgan failure.
No anti-KB001 antibodies were detected in any of the serum samples collected.
Pharmacokinetics. Respective maximum serum KB001 concentration ranges were 52,811-88,660 and 121,857-285,454 ng/mL for the 3-and 10-mg/kg-treated groups, with mean distribution volumes of 0.0525 and 0.0626 L/kg, mean elimination half-lives of 8.1 and 9.3 days, and mean serum KB001 clearances of 0.236 and 0.246 mL/hr/kg (Fig. 2 ). KB001 was detected in ETA obtained from each of these 27 treated patients, as early as D1 and up to D28, with respective peak ETA concentration ranges of 87.3-37,225 and 534-145,570 ng/mL. Their respective mean ETA/serum concentration ratios were 0.092 and 0.085. KB001 concentrations in BAL fluids obtained from patients who developed VAP postrandomization were below the assay's lower limit of detection (<80.0 ng/mL) for most patients, except for two 3-mg/kg-treated patients' samples, with a concentration of 136 ng/mL on D1 or 211 ng/mL on D3.
Clinical Outcomes. ETA-Pa counts did not change significantly in all three patient groups through D3; thereafter, too few patients had ETA samples for meaningful comparisons (data not shown).
Among the 35 patients who were included in the efficacy population, 4 of 12 (33.3%) and 4 of 13 (30.8%) patients who had received the 3-or 10-mg/kg KB001 dose, respectively, developed Pa pneumonia, vs. 6 of 10 (60%) placebo recipients. In all but two of those patients, the pneumonia diagnosis was microbiologically confirmed by BAL or ETA quantitative culture results documenting ≥10 4 or 10 5 Pa CFU/mL, respectively. For the two other patients, one each in the 3-or 10-mg/kg KB001 group, pneumonia was diagnosed at bedside by the clinician and confirmed by the "blinded" Adjudication Committee, based on clear-cut clinical manifestations and subsequent improvement with antimicrobial therapy, despite BAL quantitative culture results just below the 10 4 CFU/mL threshold. Thus, the overall documented pulmonary Painfection rate was 32% for patients who had received the antibody and 60% for those given the placebo, with an absolute difference of -28.0% (90% confidence interval, -57.7% to 1.7%), which did not achieve statistical significance. Among the seven patients colonized by ExoU + Pa, five developed pneumonia (three had received the placebo and two the 3-mg/kg KB001 dose, respectively). Two patients in the 10-mg/kg KB001 group were colonized by ExoU + Pa and neither experienced a clinical event. The respective median [range] interval between randomization and VAP onset were 5 [4] [5] [6] [7] [8] [9] , 4.5 [3] [4] [5] , and 10 [3-16] days in 3-or 10-mg/kg a Mechanical ventilation duration after randomization was censored on day 28. Data are medians (range) unless stated otherwise. 16 .0%]). No patient received antibiotics effective against Pa before he/ she developed an infection caused by this bacterium. However, the administration of antibiotics active against Pa to some patients with extrapulmonary infections in each of the three groups could have delayed the onset of pneumonia caused by this bacterium, as was the case for three, two, and one patients assigned, respectively, to the 3-mg/kg KB001, 10-mg/kg KB001, and placebo groups.
DISCUSSION
Administration of KB001, a PEGylated, recombinant anti-Pa-PcrV Fab´ antibody fragment, with potent in vitro neutralization activity against the Pa TTSS, was generally well tolerated and induced neither immunogenicity nor severe AEs. A single antibody infusion achieved high dosedependent peak serum concentrations, with prolonged elimination half-lives (≥8 days). Importantly, KB001 was rapidly (as early as D1) and consistently detected for up to 28 days in pulmonary secretions obtained from antibody-treated patients with ETA/serum concentration ratios of 8% to 9%. Although the study was not powered to demonstrate superiority of clinical end points, KB001-treated subjects had better clinical outcomes, with 50% fewer Pa pneumonias and more D28 Pa-infection-free survivors than placebo recipients. However, these differences did not achieve statistical significance.
The favorable KB001-PK profile observed herein is reassuring regarding its potential to prevent Pa VAP in ICU patients requiring prolonged MV. A single, IV, KB001 infusion not only achieved high blood concentrations for prolonged periods, but the antibody was also detected at high concentrations in the pulmonary secretions for up to 28 days in a dose-dependent manner. Indeed, an absolute prerequisite for any antibody targeting the TTSS of microorganisms colonizing the tracheobronchial tree of intubated patients is to penetrate the pulmonary secretions at concentrations able to block this virulence system for a sufficiently long time, hopefully until the patient can be weaned off the ventilator. It is likely that the in vivo KB001 half-life was further extended in our patients by conjugation of its Fab´ fragment to polyethylene glycol, as previously described for other antibody Fab´ fragments (47) . However, whether the concentrations obtained herein were sufficient to neutralize completely the TTSS system of all Pa cells present in the airways secretions of all patients is unknown. Because KB001 concentrations in the BAL fluids of patients who developed Pa VAP after randomization were below the assay's lower limit of detection for all but two patients, we hypothesize that this was probably not the case, particularly when the lower 3-mg/kg dose was used. Further studies directly investigating the 10-mg/ kg KB001 dose's in vivo efficacy at blocking the TTSS of the microorganisms that a Confidence intervals for the difference between rates for KB001-treated patients minus those for placebo recipients; b two, one, and three bloodstream infections were related to postoperative wound infection, neck abscess, and ventilator-associated pneumonia, respectively; c one bloodstream infection each was related to catheter infection, postoperative infection, and ventilator-associated pneumonia, respectively; d one bloodstream infection each was related to catheter infection and ventilator-associated pneumonia, respectively; e excluding uncomplicated urinary tract infections having not required specific antimicrobial therapy.
Data are n (%) unless stated otherwise.
colonize ICU patients' pulmonary secretions are warranted to elucidate this point. In this trial, we were unable to demonstrate any statistically significant differences between peak ETA-KB001concentrations measured in patients who developed Pa pneumonia and those who did not. However, our sample size was small and not formally calculated to answer this question. Although significantly different Papneumonia and Pa-event-free survival frequencies between the pooled KB001treated groups and placebo recipients were not found, the numerical differences observed in favor of the former (i.e., 28% lower pneumonia and 20% higher Paevent-free survival rates) were relatively large and potentially clinically relevant if confirmed by future studies. Our results are consistent with those of previous studies that associated TTSS expression with infection severity in mechanically ventilated patients, and with animal model data that demonstrated the efficacy of anti-PcrV antibodies (30, 32, 34, 35, 48, 49) . Different antibody doses, administration times, and intravenous, intratracheal, and intraperitoneal routes were all successfully tested in those studies. IV-dose efficacy required 200-400 µg of antibody/mouse, equal to ~10 mg/kg in humans. Intratracheal administration was effective at a lower dose, with 1-10 µg/mouse being protective and clearing all bacteria (30, 31) . The doses for this clinical trial were chosen based on those animal studies and preclinical safety assessments. We opted for the IV route because it achieves targeted antibody delivery to those areas of the lung that are infected and perhaps not readily accessible by the intratracheal route.
Although enhanced bacterial clearance from the lungs was demonstrated in mice infected with a potentially lethal Pa dose and given anti-PcrV antibody, KB001 apparently did not decrease the bacterial burden present in the pulmonary secretions of our antibody-treated patients, at least initially. However, the number of patients studied was small and we were unable to collect enough ETA samples after D3 to adequately examine this point.
Several limitations of our study should be mentioned, in addition to its modest sample size, which precludes any definitive conclusion regarding the clinical usefulness of the study drug. First, the results obtained apply only to a study population in which KB001 passage from the blood into the pulmonary secretions was probably greatly facilitated by the severity of the underlying inflammatory lung disease, as exemplified by prolonged MV before study entry, high disease severity scores, and high Pa burden in proximal airways (50) . Therefore, our findings cannot be extrapolated to other categories of patients, in whom the antibody penetration into the respiratory fluids might be less than that observed herein. Second, we did not use sequential BAL to determine epithelial lining fluid KB001 concentrations (with urea correction for dilution), which might have reflected KB001 penetration more precisely at the alveolar level. However, as a first step, we were mostly interested by KB001 PK in the endotracheal respiratory secretions of ICU-ventilated Pa-colonized patients, because our working hypothesis was that any antibody targeting this microorganism's TTSS to prevent VAP must be able to reach the major reservoir of bacterial cells that the tracheobronchial tree constitutes in this setting. More extensive studies of KB001 PK/pharmacodynamics in respiratory secretions are therefore warranted, both in patients and "healthy" individuals undergoing bronchoscopy for noninfective lung conditions. Third, despite our efforts to detect all Pa infections complicating the outcomes of the three study groups, some could have been missed or misdiagnosed, particularly once new antibiotics were prescribed. Notably, American Thoracic Society and Infectious Diseases Society of America guidelines do not specify a diagnostic threshold for diagnosing VAP using quantitative ETA culture results, and no consensus exists among the investigators who evaluated this technique regarding what is the best cutoff. While using 10 5 CFU/mL to define ETA positivity might misclassify some patients with only proximal airway colonization as having developed pneumonia, using a higher threshold, i.e., 10 6 CFU/ mL, might miss identification of patients with true VAP, as demonstrated by Jourdain et al (42) and other investigators (51) . That possibility explains why we decided to use a lower threshold, i.e., 10 5 CFU/ mL, in this trial, intentionally choosing to favor sensitivity over specificity, arguing that it would be worse to miss a VAP diagnosis in a study designed to assess the potential value of a preventive strategy. Be that as it may, our trial was double blinded and a strict protocol was applied, specifying that specimens for bacteriologic studies, including quantitative cultures of respiratory secretions, be obtained as soon as an infection was suspected and/ or when an intercurrent event imposed an urgent change of antibiotic therapy, regardless of the reason. Furthermore, all data pertinent to clinical outcomes were reviewed and judged by the Adjudication Committee that was blinded to the study treatment allocation.
In conclusion, we found that KB001, a recombinant, human anti-PcrV PEGylated monoclonal antibody fragment that can inhibit Pa-TTSS function, was safe and had a favorable PK profile, with predictable dose-dependent penetration into the respiratory secretions of ICU patients heavily colonized by this pathogen. Its potential for reducing Pa-VAP incidence in mechanically ventilated ICU patients warrants further investigation in larger studies.
